Pruritus Clinical Trial
Official title:
Inter-arm and Inter-period Reproducability of the Dermal Blood Flow Response After a Histamine Skin Prick.
Verified date | June 2019 |
Source | Universitaire Ziekenhuizen Leuven |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To evaluate the inter-arm and inter-period reproducibility of the dermal blood flow response induced by a skin prick of histamine, subjects will receive histamine (10 mg/ml) and negative control skin pricks on the volar surface of both forearms during two subsequent study visits to allow an intra-individual comparison. Changes in dermal blood flow will be measured during the hour after the skin pricks with laser Doppler and/or laser speckle contrast imaging.
Status | Completed |
Enrollment | 14 |
Est. completion date | May 7, 2019 |
Est. primary completion date | May 7, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Subject is a white male = 18 and = 45 years of age at the time of screening - Subject is a nonsmoker for at least 6 months prior to the study start - Subject has a body mass index = 18 and = 30 kg/m2 - Subject has a clear increase in histamine-induced dermal blood flow - Subject is judged to be in good health on the basis of medical history, physical examination and vital signs - Subject understands the procedures and agrees to comply with them for the entire length of the study by giving written informed consent Exclusion Criteria: - Subject has excessive hair growth on the volar surface of the forearm - Subject has a past or present history of diffuse dermatological conditions including eczema, scleroderma, psoriasis, urticaria, dermatographism and dermatitis - Subject has any abnormality on the skin of the forearm, possibly interfering with the study assessments including tattoos, keloids, tumors, ulcers, burns, flaps and grafts - Subject cannot avoid excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover the forearms 24 hours before and after each study visit - Subject currently uses lotions, oils, depilatory preparations, makeup or other topical treatments on the arms and on a regular basis which cannot be discontinued for the duration of the study; subject has used any topical treatments within 7 days of the start of the study - Subject has a past or present history of (symptomatic) asthma - Subject has a history of severe allergic reactions to food or drugs or adverse experiences of a serious nature related to the administration of either a marketed or investigational drug, including histamine - Subject currently uses any prescription or nonprescription drugs on a regular basis which cannot be discontinued for the duration of the study; subject has used any prescription or nonprescription medication within 14 days of the start of the study - Subject is a habitual and heavy consumer of coffee or caffeinated beverages (more than approximately 4 cups of tea, coffee or cola per day) at the time of the study. Subjects who have reduced their consumption to = 4 cups per day at least 1 week prior to enrollment may participate. Subjects who cannot refrain from caffeinated beverages 24 hours before the study visit; - Subject is unable to refrain from drinking alcohol 24 hours prior to histamine application, is currently a regular user (including "recreational use") of any illicit drugs, or has a history of drug (including alcohol) abuse. A drug screen will include amphetamines/ methamphetamines, methylenedioxymethamphetamine, benzodiazepines, barbiturates, cocaine, cannabis, tricyclic antidepressants, methadone and opiates - Subject cannot refrain from being around second hand smoke 24 hours prior to histamine application or uses nicotine-containing products. Ex-smokers should have ceased smoking at least 6 months prior to screening - Subject has any of the following vital sign measurements at screening: heart rate = 40 or = 100 beats/min, diastolic blood pressure = 50 or = 89 mmHg and/or systolic Blood Pressure = 90 or = 139 mmHg - Subject has been involved in testing an investigational drug in another clinical study within the last 4 weeks or 5 half-lives - Subject has evidence of a clinically significant active infection, fever of 38°C or above at the time of the study visits - Subject has a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs - Subject is in a situation or has a condition, which, in the opinion of the investigator, may interfere with safe and optimal participation in the study - Subject has a history of any illness or disorder, which, in the opinion of the investigator, might confound the results of the study. |
Country | Name | City | State |
---|---|---|---|
Belgium | Center for Clinical Pharmacology | Leuven |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in dermal blood flow induced by histamine skin pricks, compared to baseline and placebo in terms of inter-period and inter-arm reproducability | The dermal blood flow will be assessed before (baseline) and every 5 minutes during the hour following the skin pricks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05038982 -
Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin
|
Phase 2 | |
Completed |
NCT04510090 -
Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus
|
Phase 1 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Terminated |
NCT01825655 -
Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching
|
Phase 4 | |
Completed |
NCT01236859 -
Gabapentin for Prophylaxis Intrathecal Morphine-Induced Pruritus
|
N/A | |
Completed |
NCT00782054 -
Evaluation of Post Burn Rehabilitation Population for Itch Control
|
Phase 4 | |
Completed |
NCT04999787 -
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of HSK21542 Injection in Liver Disease Subjects With Pruritus
|
Phase 2 | |
Recruiting |
NCT04256759 -
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus
|
Phase 2 | |
Completed |
NCT04337073 -
The Effect of Propofol on Dexamethasone-induced Perineal Pruritus
|
Early Phase 1 | |
Completed |
NCT04415034 -
Scalp Pruritus Measurement Using Visual Analog Scale and 5-d Itch Scale in Children With Pediculosis Capitis
|
||
Active, not recruiting |
NCT05525520 -
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
|
Phase 2 | |
Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
Completed |
NCT04399525 -
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
|
N/A | |
Recruiting |
NCT02432508 -
Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis
|
N/A | |
Completed |
NCT02653703 -
L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain
|
N/A | |
Completed |
NCT01963793 -
Topical Aprepitant in Prurigo Patients
|
Phase 2 | |
Completed |
NCT01232985 -
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
|
Phase 2 | |
Not yet recruiting |
NCT00577967 -
Gabapentin - A Solution to Uremic Pruritus?
|
N/A | |
Recruiting |
NCT06120907 -
Swiss Itch Registry
|
||
Recruiting |
NCT04589429 -
Adding Nalbuphine for Control of Intrathecal Morphine Pruritus
|
Phase 2 |